IL193103A - Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders - Google Patents

Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders

Info

Publication number
IL193103A
IL193103A IL193103A IL19310308A IL193103A IL 193103 A IL193103 A IL 193103A IL 193103 A IL193103 A IL 193103A IL 19310308 A IL19310308 A IL 19310308A IL 193103 A IL193103 A IL 193103A
Authority
IL
Israel
Prior art keywords
hydroxy
ethylaminoimethyl
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
Prior art date
Application number
IL193103A
Other languages
English (en)
Hebrew (he)
Other versions
IL193103A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL193103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL193103A0 publication Critical patent/IL193103A0/en
Publication of IL193103A publication Critical patent/IL193103A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IL193103A 2006-02-10 2008-07-29 Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders IL193103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Publications (2)

Publication Number Publication Date
IL193103A0 IL193103A0 (en) 2009-02-11
IL193103A true IL193103A (en) 2013-06-27

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193103A IL193103A (en) 2006-02-10 2008-07-29 Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders

Country Status (33)

Country Link
US (1) US7960551B2 (https=)
EP (1) EP1981872B1 (https=)
JP (1) JP5616021B2 (https=)
KR (1) KR101488691B1 (https=)
CN (1) CN101379057B (https=)
AR (2) AR059409A1 (https=)
AU (1) AU2007213767B2 (https=)
BR (1) BRPI0707559B8 (https=)
CA (1) CA2641769C (https=)
CR (1) CR10227A (https=)
CY (1) CY1119238T1 (https=)
DK (1) DK1981872T3 (https=)
EA (1) EA016580B1 (https=)
ES (1) ES2640226T3 (https=)
GB (1) GB0602778D0 (https=)
HR (1) HRP20171304T1 (https=)
HU (1) HUE034315T2 (https=)
IL (1) IL193103A (https=)
JO (1) JO3389B1 (https=)
LT (1) LT1981872T (https=)
MA (1) MA30273B1 (https=)
MY (1) MY153656A (https=)
NO (1) NO341343B1 (https=)
NZ (1) NZ570242A (https=)
PE (2) PE20110120A1 (https=)
PL (1) PL1981872T3 (https=)
PT (1) PT1981872T (https=)
SG (1) SG169404A1 (https=)
SI (1) SI1981872T1 (https=)
TW (1) TWI401251B (https=)
UA (1) UA100364C2 (https=)
WO (1) WO2007090859A1 (https=)
ZA (1) ZA200806782B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5540075B2 (ja) * 2009-04-14 2014-07-02 グラクソ グループ リミテッド ビフェニル−２−イルカルバミン酸エステルの調製方法
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2011011156A (es) * 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
JP6019118B2 (ja) * 2011-08-02 2016-11-02 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 吸入に適した酸化型アビジンの医薬品組成物
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
CA2133083A1 (en) 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
MXPA04009916A (es) 2002-04-12 2005-05-03 Boehringer Ingelheim Pharma Medicamento que contiene betamimeticos y un nuevo anticolinergico.
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Also Published As

Publication number Publication date
TW200800948A (en) 2008-01-01
AR104288A2 (es) 2017-07-12
US7960551B2 (en) 2011-06-14
UA100364C2 (xx) 2012-12-25
PE20071249A1 (es) 2008-01-16
BRPI0707559B8 (pt) 2021-05-25
KR20080114723A (ko) 2008-12-31
LT1981872T (lt) 2017-09-11
SG169404A1 (en) 2011-03-30
BRPI0707559B1 (pt) 2021-01-12
ZA200806782B (en) 2009-10-28
MA30273B1 (fr) 2009-03-02
EP1981872A1 (en) 2008-10-22
AR059409A1 (es) 2008-04-09
HRP20171304T1 (hr) 2017-10-20
JP5616021B2 (ja) 2014-10-29
CN101379057B (zh) 2013-02-13
ES2640226T3 (es) 2017-11-02
EA016580B1 (ru) 2012-06-29
SI1981872T1 (sl) 2017-10-30
NO341343B1 (no) 2017-10-16
US20070281971A1 (en) 2007-12-06
CR10227A (es) 2008-10-29
MY153656A (en) 2015-03-13
WO2007090859A1 (en) 2007-08-16
DK1981872T3 (en) 2017-09-11
PE20110120A1 (es) 2011-03-08
CY1119238T1 (el) 2018-02-14
JO3389B1 (ar) 2019-03-13
JP2009526018A (ja) 2009-07-16
NZ570242A (en) 2011-09-30
EP1981872B1 (en) 2017-06-21
TWI401251B (zh) 2013-07-11
CA2641769C (en) 2014-02-04
BRPI0707559A2 (pt) 2011-05-10
CN101379057A (zh) 2009-03-04
NO20083425L (no) 2008-09-09
KR101488691B1 (ko) 2015-02-02
GB0602778D0 (en) 2006-03-22
EA200801691A1 (ru) 2009-02-27
PT1981872T (pt) 2017-09-13
CA2641769A1 (en) 2007-08-16
PL1981872T3 (pl) 2017-11-30
AU2007213767A1 (en) 2007-08-16
AU2007213767B2 (en) 2012-04-26
BRPI0707559A8 (pt) 2019-01-29
HUE034315T2 (en) 2018-02-28
IL193103A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
IL193103A (en) Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders
TW200613296A (en) Crystalline form of a biphenyl compound
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
SI2024341T1 (sl) Novi postopek za statine in njihove farmacevtsko sprejemljive soli
ZA201000586B (en) Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
CL2013000870A1 (es) Solvato de isopropanol e hidrato de la sal oxalato cristalina del 1-(2-([4-(4-([(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil)fenilcarbamoil)butil]metilcarbamoil)etilpiperidin-4-il ester del acido bifenil-2-ilcarbamico; composicion farmaceutica; y uso para tratar una enfermedad pulmonar, epoc y asma.
HUS2000053I1 (hu) Kinolinszármazékok és gyógyászati készítményeik
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
IL223126A (en) METHOD FOR PREPARING 5,4-DIETOXYCY-TETRAYDROFORAN-2-IL-METHYL ESTER ACETIC ACID AND THE SPACIAL ISOMERS
IL232459A0 (en) Quinolone compound and pharmaceutical preparation
EP2345416A4 (en) PHARMACEUTICAL COMPOSITION FOR CLEANING VENES AND MANUFACTURING METHOD THEREFOR
GB201009713D0 (en) A pharmaceutical composition for treating diabetes and preparation methods thereof
EP2119436A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
ZA201006031B (en) Pharmaceutical composition comprising racetam and carnitine and process for its preparation
ZA200804492B (en) S-Omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
IL215550A (en) Process for the preparation of a biphenyl ester 2-carboxylic acid moiety 1– [2–2] -chloro-4-formyl-5-methoxyphenyl) -carbamoylethyl] piperidene-4 ester yl and intermediate
PL2435406T3 (pl) Rozdzielanie (±)-fenylo[4-[4-[[[4'-(trifluorometylo)-2-bifenylilo]karbonylo]amino]fenylo]-1-piperydynylo] octanu metylu
HK1140410A (en) Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed